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1. Introduction
An estimated 166,900 patients were diagnosed with malignant melanoma in developed
countries last year [1]. The reported incidence of malignant melanoma continues to rise de‐
spite increasing understanding of its aetiology. In the United States 76,250 new cases are ex‐
pected in 2012 with melanoma far outstripping other skin cancers in terms of mortality [2].
Similarly, in the UK, 12,818 new cases of malignant melanoma were diagnosed in 2010 [3].
Approximately, 85% percent of patients with cutaneous melanoma are diagnosed at a local‐
ized stage, while 10% have associated regional lymph node involvement and 5% of patients
will have distant metastatic disease at presentation. The corresponding 5-year overall sur‐
vival rates are 98.2% for localized disease, 62.4% for regional lymph node involvement and
15.1% for distant melanomas [4, 5].
Advances in the understanding of the molecular mechanisms and immunology of mela‐
noma  have  lead  to  the  development  of  promising  novel  therapeutic  agents.  Surgery,
however,  remains the mainstay of treatment and changes in the surgical  approach have
been guided by the greater  understanding of  melanoma pathogenesis.  The management
of the primary tumour has become more conservative, with acceptance of narrower exci‐
sion margins. In addition, there has been a move away from the routine performance of
elective regional lymph node dissection towards sentinel lymph node biopsy which is as‐
sociated with less morbidity [6].
The new American Joint Committee on Cancer (AJCC) guidelines for the staging of melano‐
ma were introduced into clinical practice in 2010 [7]. The two most important distinctions
with previous guidelines are the incorporation of the mitotic rate of the primary tumor and
the key role of the sentinel lymph node, including methods of analysis, in accurately staging
clinically occult nodal disease [8].
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The purpose of this chapter is twofold. Firstly, this chapter describes the appropriate surgi‐
cal management of the primary tumour, the associated regional lymph node basin and dis‐
tant metastatic disease. Secondly, the updated and revised AJCC staging system will be
discussed and current controversies addressed.
2. Risk factors
The worldwide incidence of melanoma doubles every ten to fifteen years [9]. Risk factors
associated with the development of malignant melanoma are varied and include genetic
susceptibility,  exposure  to  ultraviolet  radiation,  and immunologic  factors.  The  most  im‐
portant  of  these  is  ultraviolet  exposure  where  intermittent,  unaccustomed sun exposure
and sunburn were found to have considerable roles as risk factors for melanoma. How‐
ever, despite the increase in public awareness, the practice of ultraviolet radiation protec‐
tion  behaviour  is  low.  Also  worryingly  a  survey  performed  in  the  US  in  2005
documented that  up to  14% of  adults,  primarily  women and young adults  used an in‐
door tanning device on at least one occasion [10].
Epidemiological studies have found that blue, green or grey eyes, blonde or red hair, light
complexion, freckles, sun sensitivity, and an inability to tan, are risk factors for the develop‐
ment of melanoma [11, 12]. Countries with close proximity to the equator with predomi‐
nantly fair-skinned populations have shown a higher preponderance to developing
melanoma. Risk factors for melanoma also include a positive family history or personal his‐
tory of melanoma/non-melanoma cancer or in-situ skin carcinomas, large numbers of mela‐
nocitic naevi in childhood, and xeroderma pigmentosum [13].
It is suggested that minimising radiation, and the adoption of photo-protective measures,
can significantly reduce the risk of developing melanoma [13-15].
3. Surgery
3.1. Initial surgical biopsy
Melanoma  can  develop  either  in  a  pre-existing  pigmented  lesion  or  de  novo.  Features
raising  suspicion  of  melanoma  in  a  pre-existing  pigmented  lesion  include  a  change  in
size, irregular shape, irregular colour, diameter 7 mm or more, inflammation, oozing or a
change in sensation [5,16]. The ABCD system of diagnosis (Asymmetry, Border irregulari‐
ty, Colour change, and a Diameter greater than 6 mm) has also been advocated to assist
early clinical diagnosis, to which 'E' (Evolving or Elevation) has been added [5,17,18]. Ta‐
ble 1 illustrates the seven point checklist  and ABCDE system for the assessment of pig‐
mented lesions.
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Seven point checklist The ABCDE lesion system
Major features
Change in size A Geometrical Asymmetry in 2 axes
Irregular shape B Irregular Border
Irregular colour C At least 2 different Colours in lesion
Minor features D Maximum Diameter >6mm
Largest diameter 7mm or more E Elevation
Inflammation
Oozing
Itch/ change in sensation
Table 1. Seven point checklist and ABCDE system for assessment of pigmented lesions [19]
An excision biopsy is indicated for lesions suspected of being a melanoma. An excision bi‐
opsy is the recommended method for suspected malignant melanoma as it enables diagno‐
sis and staging of the tumour and may determine future treatment and prognosis [20, 21].
The whole lesion should be excised with a 1-3 mm margin of normal skin including sub-der‐
mal fat. It is crucial to plan this excision carefully with a view towards definitive treatment.
Knowledge of lymphatic drainage and subsequent need for sentinel node biopsy should
lead to narrow margin excision potentially avoiding interference with subsequent lymphatic
mapping. In addition, a longitudinal orientation is preferred in the extremities and incision
orientation should be along Langer’s lines on the trunk. This allows for subsequent closure
of a wide local excision and reduces the need for skin grafting if primary closure is to be
achieved.
In certain areas (such as the face, palm of hand, sole of foot, ears, digits and subungal le‐
sions) an excision biopsy may not be appropriate. In these cases, an incisional or punch bi‐
opsy of the thickest portion of the lesion may be performed [21]. Shave biopsy is avoided as
it makes characterising the lesion difficult by underestimating tumour thickness, which is
important in determining further treatment [21]. It also risks leaving residual tumour at the
radial and deep margins.
Obtaining an adequate biopsy specimen is crucial for histopathological diagnosis and tu‐
mour staging. The tumour thickness, which remains the most powerful prognostic parame‐
ter, provides a guide to the margin clearance required for delayed wide excision and need
for adjuvant therapy [20, 22]. Pathological examination should evaluate macroscopic fea‐
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tures of the tumour such as width, symmetry, and circumscription, and microscopic features
such as ulceration, microsatellitosis, angiolymphatic invasion and mitotic rate [22].
3.2. Management of the primary tumour
The surgical management of the primary tumour has shifted from extensive surgical resec‐
tion, which was not only debilitating but also disfiguring, to a more conservative approach.
A multidisciplinary team in a tertiary referral centre should ideally manage patients with
malignant melanoma. This team should include: a surgeon, dermatologist,,medical oncolo‐
gist, pathologist, radiologist, counsellor, specialist nurse and palliative care specialist [23].
Pathological assessment of the surgically excised biopsy specimen allows for staging of the
tumour while the thickness of the melanoma at initial biopsy serves as a guide to the subse‐
quent resection. The Breslow thickness, which is the most important prognostic indicator of
localised disease, is defined as the distance of invasion and is measured from the granular
layer of the epidermis to the point of deepest invasion by tumour cells [5, 24, 25].
Large randomised controlled trials have been performed in an attempt to elucidate the opti‐
mal resection margin in melanoma of various thickness (thin, intermediate, and thick mela‐
nomas) [26-31]. The trials reported data with not only differing lengths of follow-up but also
differing margin excision widths. Therefore interpretation of the results is largely restricted
to survival outcomes as a result of this heterogeneity.
The management of lentigo maligna and in situ melanoma present unique problems because
of the characteristic, yet unpredictable, subclinical extension of atypical junctional melano‐
cytic hyperplasia, which may extend several centimeters beyond the visible margins [33].
There are no randomized trials looking at the optimal resection margin in these lesions.
Guidelines from the American Academy of Dermatology in 2011 recommend a resection
margin of 0.5 to 1.0 cm for melanoma in situ [34]. The NCCN recommends a margin of 0.5
cm around the visible lesion. For large in-situ lentigo maligna melanoma, it is felt that surgi‐
cal margins greater than 0.5 cm may be necessary to achieve a histologically negative mar‐
gin [33]. More recently, topical imiquimod has been used in lentigo melanoma treatment
prior to definitive surgical resection. In a study that included 40 patients, 33 of these were
found to have a complete clinical response after the use of imiquimod 5% cream. On histo‐
logical review, 30 of the patients had no evidence of melanoma. While studies have shown a
limited role for this treatment, it does not replace surgery [35].
Three main trials (The World Health Organisation Trial, Swedish Melanoma Study and the
French Cooperative Group) looked at the optimal resection margin for T1 and T2 melano‐
mas. The World Health Organisation (WHO) trial included 612 patients with melanomas
less than 2.0mm with patients being randomly assigned to a wide local excision with a either
a 3cm margin or 1cm margin. At 12 years of follow up, similar survival rates between the
groups were noted (87% and 85% respectively) with no statistically significant difference in
recurrence dependent upon margin width. As a consequence of this trial recommendations
were made that a 1cm margin be used for melanomas ≤1mm. Similarly, the Swedish Mela‐
noma Study Group studied 989 patients with melanomas 0.8 to 2mm thick who were ran‐
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domly assigned to either a 2cm or 5cm resection margin. At a median follow-up of 11 years
the local recurrence rate for all groups was less than 1%. Again there was no significant dif‐
ference noted in the overall or disease-free survival between the two groups. A third trial,
the French Cooperative Group, included 362 patients with melanomas ≤2mm in thickness.
Patients were randomly assigned to a wide local excision with either a 2cm or 5cm resection
margin. No difference was noted between the groups in terms of local recurrence or overall
survival. Therefore at present, a resection margin of 1cm is recommended for melanomas
<1mm and 2cm for melanomas 1 - 2mm thick [26-28].
Melanomas between 2 - 4mm are considered intermediate thickness melanomas. Once
again, there are a number of trials looking specifically at this cohort of patients which failed
to show a benefit of greater than a 2cm excision margin. The Melanoma Intergroup Trial in‐
cluded 468 patients with melanomas of 1 to 4mm thickness. Patients were randomly as‐
signed to an excision margin of either 2cm or 4cm. Forty two percent of patients in the
group undergoing 2cm excision had a melanoma thickness >2.0mm, while 46% of patients in
the 4cm resection group had melanomas >2.0mm. At mean follow up, a 2cm margin was
shown to be as effective as a 4cm margin in both the local control and overall survival for
patients with intermediate thickness melanomas. Local recurrence however, was primarily
determined by the thickness of the primary lesion and the presence or absence of ulceration
[29, 30]. A multi-centre European trial was also performed to tease out the need for wider
margins in deeper, intermediate thickness melanomas. In total, 936 patients were included
who were assigned randomly to have either a 2cm or 4cm resection margin. At a follow-up
of almost 7 years there was no statistically significant difference noted for recurrence or sur‐
vival between the two groups [31]. Finally a British trial was performed which recruited 900
patients with lesions greater than 2mm to a wide local excision with either a 1cm or 3 cm
margin Interestingly, this study demonstrated a higher local recurrence rate when a 1cm
margin was used. However, there was no statistically significant difference noted in overall
survival. The authors therefore concluded that a margin of 1cm should be restricted to pa‐
tients with a melanoma thickness of less than 2mm [32]. Therefore, at present a 2cm excision
margin is recommended for intermediate (2 – 4mm) thickness melanomas.
There is unfortunately limited evidence or published data on the optimal resection margin
for melanomas with a thickness of 4mm or greater. The British Trial included 243 patients
with melanomas of > 4mm thickness and the results showed a higher local recurrence rate
associated with a margin of 1cm [32]. However, the local recurrence rates with a 3cm margin
appeared similar to other trials with only a 2cm margin of excision. In a retrospective review
from MD Anderson which assessed patients with melanomas of greater than 6mm thick‐
ness, excision margins greater than 2 cm were not found to effect overall survival when
compared to margins of 2cm or less. The 5-year overall and disease free survival rates were
55% and 30% in node negative compared to node positive patients which were included in
the study. Nodal status, thickness, and ulceration were significantly associated with overall
survival by multivariate analysis. However, the neither the disease free nor overall survival
was effected by the presence of a local recurrence or the original excision margin in this
study [36]. The study authors therefore concluded that a 2 cm margin of excision is adequate
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for patients with thick melanoma [36].However, overall there is insufficient data to support
the preferred use of either a 2cm or 3cm margin, and consequently, it may be reasonable to
allow the patient to decide, following an informed discussion of surgical options. The use of
the larger 3cm margin may be recommended in patients with deep tumours (> 4mm depth),
due to the higher risk of loco-regional recurrence [32]. In selected cases, however, margin
size may be modified to accommodate individual anatomic or cosmetic considerations [23].
Although radial excision margins remain somewhat controversial, the depth of excision in
clinical practice is defined as an excision down to but not including the deep fascia [37]. This
definition has been internationally accepted and forms the basis of the current gold-stand‐
ard management of melanoma. Unfortunately in facial areas where the 'deep fascia' is less
clearly defined (for example, on the ear, nose, or eyelid), or other anatomic sites such as over
the breast, existing studies provide no clear guidelines for optimal depth of excision [5].
Margins
Tis Histologically clear margins are adequate
T1 1cm margin is recommended
T2 1-2cm margin recommended
T3 2-3cm margin recommended
Table 2. Recommended excision margins based on tumor size [23]
Despite all the evidence discussed above, controversy still remains regarding the optimal
width of the surgical excision margins in malignant melanoma and current evidence is not
sufficient to address the optimal surgical management for all melanomas. Indeed a Co‐
chrane review which has been recently published attempted to address this complex ques‐
tion [5]. Overall, there was no statistically significant difference in overall survival between
either a narrow or wide excision, but this meta-analysis was confounded by the fact that ex‐
cision margins were not standardized between studies within the overall analysis. Therefore
the dilemma regarding surgical margin remains. However, guidelines regarding margin
width have been published and should be adhered to where feasible. Further studies are re‐
quired to determine the appropriate local treatment for thick melanoma which has not been
comprehensively addressed in trials thus far.
3.3. In-transit metastasis
The treatment of advanced or recurrent melanoma remains controversial. Around 10% of
patients develop in-transit or multiple cutaneous metastases but at least half will survive for
two years without developing distant disease [38, 39]. Unfortunately, the 5-year survival has
been reported as 12% with a median survival of 19 months [39].
In-transit metastases are defined as cutaneous or subcutaneous deposits of melanoma be‐
tween the site of the primary disease and regional lymph nodes [40]. These deposits may be
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found localized around the primary tumour or may be widespread throughout the affected
limb or on the head and neck or trunk, depending on the primary site [40] (Figure 1). It is
thought that these metastases arise from dissemination of melanoma cells via the lymphatics
to tissues located between the primary tumor and the regional lymph node basin. Other the‐
ories include that of drift metastases within tissue fluid of the limb or the local implantation
of circulating haematogenous melanoma cells [41, 42].
The presence of small in-transit metastatic melanoma presents specific surgical problems.
Unlike nodal disease, which can be managed by regional lymph node dissection, in-transit
disease is often widespread and may necessitate multiple surgeries as the disease progresses
and new deposits become apparent. In its most severe form, in-transit metastasis may be‐
come severely disabling and may be refractory to treatment. Treatment is therefore, pallia‐
tive, even if staging investigations fail to show evidence of distant metastatic disease [40].
Recent studies have recommended that treatment should be tailored to the extent of the dis‐
ease, with treatments associated with significant morbidity being reserved for bulky ad‐
vanced metastases [40].
Several therapies have been proposed for the management of in-transit metastasis including
surgery, radiotherapy, and intra-lesional therapy. In-transit metastasis are sharply circum‐
scribed with a clear line of demarcation from normal dermis and epidermis. This line does
not contain any in-situ component. Therefore, wide excision margins are not recommended
for these lesions and a complete macroscopic excision and primary closure is sufficient. If
lesions are grouped closely together, an en bloc excision is acceptable [40].
Figure 1. In-transit metastases on the left lower limb
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There are numerous treatments available for the management of in-transit metastases that
are not suitable for surgical treatment. Carbon dioxide laser therapy has been used in the
management of small in-transit metastasis that are not amenable for surgical excision. This
is performed as a day case under local anesthetic. Small lesions may be vaporized complete‐
ly, while larger lesions are first circumscribed with the laser prior to excision of the central
core. This well tolerated procedure is more suitable for smaller lesions.
In more advanced diseased, isolated limb perfusion has traditionally been the main method
of treatment. This invasive procedure has been replaced by isolated limb infusion, which is
simpler, minimally invasive, and a more economical alternative with comparable results [38,
39]. Isolated limb perfusion with chemotherapeutic agents was developed in New Orleans
in the mid 1950s by Creech et al [38, 39, 43]. It is based on the principle of vascular isolation
of the affected limb using a cardiopulmonary bypass circuit through open surgical cannula‐
tion of the major limb vessels. This procedure is technically difficult, expensive, and compli‐
cations are common. Repeated limb perfusions are difficult to perform and morbidity rates
increase from 28% to 51% [38]. A simpler alternative, isolated limb infusion was developed
by Dr John Thompson in the Sydney Melanoma Unit [44]. It is a less invasive procedure,
which involves percutaneous placement of venous and arterial catheters and the infusion of
chemotherapeutic agents. This negates the need for a bypass circuit. As opposed to isolated
limb perfusion, autologous blood or autologous transfusion of allogenic units is not re‐
quired. The operating time is reduced from four hours to one hour, and the complication
rates are documented to be lower, at only 1% [38, 43].
The presence of in-transit metastases indicates a poor prognosis. The development of in-
transit disease may be rapidly followed by distant metastases [40]. The American Commit‐
tee on Cancer Staging (AJCC) classify it as stage IIIB or IIIC disease, along with regional
lymph node metastases. Five year survival rates in patients with stage III disease ranges
from 18% to 60%. However, patients with in-transit metastasis have the worst prognosis,
with 5 year survival of approximately 25%.
3.4. Reconstruction
The optimal treatment of patients undergoing melanoma excision is primary closure of the
wound. Unfortunately, this is not always possible especially in patients with thick melano‐
mas requiring wider excision margins. Therefore, in these cases reconstructive surgery must
be considered and where feasible offered to the patient. This will usually depend on the site
and extent of the excision to be performed. Skin grafting is the commonest technique em‐
ployed to ensure skin cover of the anatomical defect. Traditionally, the graft is harvested
from the contralateral limb, as melanoma was thought to metastasize primarily via lymphat‐
ic routes [15, 45, 46]. However, a recent study looking at the recurrence rates within skin
graft donor sites, reported no difference in local recurrence rates when either the ipsilateral
or contralateral limbs were used as graft sites. The authors of this study recommended that
to improve patient recovery, harvesting the graft from the same limb as the primary tumor
is both oncologically safe and technically superior to contralateral skin graft harvest [47]. In
certain sites, such as the head and neck, the use of skin grafts may not always be ideal and
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may result in significant deformity. Local rotation flaps, such as rhomboid flaps, have been
found to be safe, versatile, and more aesthetically pleasing when used in these areas [15, 48].
4. Management of the regional lymph node basin
The presence of regional lymph node metastatic disease is a significant predictor of out‐
come in melanoma and is associated with a 50% reduction in overall survival compared
to that of patients without nodal involvement [23].  Indeed the regional lymph node sta‐
tus is thought to be the most powerful prognostic indicator in clinically localised melano‐
ma. The risk of patients developing lymph node metastases increases exponentially with
the increasing thickness of the primary melanoma. Melanomas less than 1mm rarely met‐
astasise  (less  than 10%),  while  at  least  25% of  melanomas 1.5-  4.0mm and over  60% of
melanomas  greater  than  4.0mm  thick  will  have  lymph  node  metastasis  at  presenta‐
tion[49].  These  data  form the  basis  for  the  current  guidelines  on which patients  should
be offered a sentinel lymph node biopsy.
Patients with melanoma can present with either a clinically normal regional lymph node ba‐
sin or palpable regional lymphadenopathy. Patients with stage III disease commonly have
clinically negative lymph nodes but are found to have micro-metastatic disease on their sen‐
tinel lymph node biopsy. Such patients have been found to have a more favourable outcome
than patients with clinically involved nodes at presentation [8]. The outcome of patients
with stage III disease is determined by the number of metastatic nodes and the presence of
either microscopic or macroscopic disease. The 5-year survival rate for patients with stage
IIIA disease is 67%, and the 10-year survival is 60%. Patients with stage IIIB disease have
survival rates estimated at 53%, while stage IIIC disease patients have the worst prognosis
with a 5-year survival of approximately 26% [49]. The surgical management of the associat‐
ed lymph node basin depends on the initial presentation of the patient.
4.1. The sentinel lymph node biopsy
Metastasis to regional lymph nodes is an important prognostic factor in patients with mela‐
noma, upstaging patients to stage III disease and has been shown to occur in about 20% of
patients with intermediate thickness melanoma [50]. A sentinel lymph node biopsy (SLNB)
is a minimally invasive procedure that aims to identify patients with microscopic lymph
node metastasis who would benefit from further lymph node dissection and adjuvant treat‐
ment. The sentinel node is defined as any lymph node that receives lymphatic drainage di‐
rectly from a primary tumour site [51] (Figure 2).
The technical details of sentinel lymph node biopsy can be broken down into a number of
steps. First, the patient undergoes preoperative lymphoscintigraphy which identifies the re‐
gional nodal basin and estimates the location of the sentinel node. Four intra-dermal injec‐
tions of 0.1–0.2 ml of 10 MBq radio-colloid are performed around the melanoma or
melanoma scar: the injection should raise a small wheal on the skin. The most commonly
used radiotracers are 99mTc-labeled albumin (Europe), 99mTc-labeled sulphur colloid and
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99mTc-antimony trisulphide colloid. Scintillation cameras are used to obtain dynamic im‐
ages. These images allow identification of sentinel nodes within the regional nodal basin.
They also allow discrimination of second-tier nodes, which may be falsely interpreted as
sentinel nodes on delayed imaging. The surface location of the sentinel node may be marked
on the skin preoperatively or, alternatively, a gamma probe can be use to locate the node
intra-operatively. Intra-operative lymphatic mapping involves injection of vital blue dye
(Isosulfan blue (Lymphazurin), Methylene Blue or Patent Blue V are used). A combination
of radiotracers and blue dye has been shown to allow sentinel node identification in 99% of
cases. The blue dye is injected intra-dermally in 2-4 locations at the site of the primary le‐
sion, 10-15 minutes before skin incision. The dye is used to visualize the sentinel node intra-
operatively. A gamma probe (covered in a sterile plastic sheath), which detects radiation,
may be used to locate the sentinel node (Figure 3). Counts should be obtained over the skin
before incision, to confirm the location of the sentinel node. A short skin incision is made,
bearing in mind the potential need for complete lymph node dissection. The sentinel nodes
are then identified using the blue dye and gamma probe as a guide, and they are removed
with minimal dissection. An ex-vivo count should be obtained, by measuring the radioactiv‐
ity of the sentinel node(s) after removal. A bed count is then also obtained following remov‐
al of the sentinel node(s), to ensure that no sentinel nodes remain [15, 52].
Figure 2. The Sentinel Lymph Node Biopsy
The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) is the largest trial to address
the role of lymphatic mapping with SLNB in determining prognosis and its impact on sur‐
vival [53]. Patients with a primary cutaneous melanoma were randomly assigned to wide
excision and postoperative observation of the regional lymph nodes with lymphadenectomy
being performed only if nodal relapse was confirmed or to wide excision and sentinel-node
biopsy with immediate lymphadenectomy if nodal micro-metastases were detected on biop‐
sy [53]. The MSLT-1 trial confirmed the prognostic importance of SLN status, demonstrating
that SLN status is the most statistically significant predictor of survival for clinically local‐
ized (stage I/II) intermediate thickness melanoma (1.2 to 3.5 mm). The 5-year disease-free
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survival for patients with positive SLN status was 72.3%, compared to 90.2% in those with
negative SLN status [53].
Figure 3. Gamma probe used to locate sentinel lymph node
The AJCC Melanoma Staging Committee recommends that a sentinel lymph node biopsy be
performed as a staging procedure in patients for whom the information will be useful in
planning subsequent treatments and follow-up regimens. Significant controversy surrounds
the use of sentinel lymph node biopsy in thin, early melanomas. There are a number of rea‐
sons for this. Firstly, patients with a low-risk of nodal metastases are exposed to the morbid‐
ity of a potentially unnecessary procedure. Secondly, the routine use of sentinel lymph node
biopsy is expensive: global application of sentinel lymph node biopsy in all patients is esti‐
mated to cost between $700,000 and $1,000,000 for every sentinel node metastasis detected
[15, 54]. Therefore, for thin melanomas, the routine use of SLNB has not been advocated as
the risk of positive nodes is around 5.1% [55]. Indeed, a rate of only 2.7% has been docu‐
mented with melanomas thinner than 0.75mm [55]. SLNB may be considered, however, in
patients with high risk features such as ulceration, a mitotic rate of greater than or equal to
1/mm2 especially in patients with melanomas of ≥ 0.76 mm as they are associated with an
approximately 10% risk of occult metastases in their sentinel lymph nodes [8]. SLNB is also
recommended for patients with intermediate thickness melanoma (2 – 4mm). With regards
to thick melanomas, it is expected that around 30% of patients will have evidence of lymph
node involvement and the role for SLNB is less clear. It is, however, recommended that
SLNB be performed in patients with no clinically evidence positive nodes as it allows for
better chances at local disease control [50].
Recent editions of the AJCC melanoma guidelines have altered the criteria for the presence
of regional lymph node disease. Originally, the 6th Edition of the AJCC melanoma guidelines
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recommended histological confirmation of all immunohistochemically (IHC) detected meta‐
stasis by routine H&E staining and only after this confirmation could metastatic disease be
documented [56]. However, the more recently published guidelines state that positive nodes
may be confirmed by either H&E staining or IHC staining with melanoma associated mark‐
ers [7]. The three most commonly used IHC markers for melanoma are S-100, HMB-45, and
Melan A/MART 1. Currently, S-100 remains the most sensitive marker for detection of mela‐
noma, while HMB-45 and Melan A/MART 1 are used for their specificity [57].
More recently, reverse transcriptase polymerase chain reaction (RT-PCR) has been shown to
be a promising staging tool used to identify patients with histologically unidentified micro-
metastatic disease. This technique relies on detection of distinct mRNA expressed by mela‐
noma cells, such as tyrosinase, MAGE-3, MART-1, gp100 and other markers [58, 59]. There
has been evidence suggesting the correlation between RT-PCR positive results in blood with
stage of melanoma, tumor thickness and known prognostic indicators. The value of RT-PCR
in regional lymph nodes is less clear. The number of false positives due to the presence of
melanocytic naevi and Schwann cells has limited its use. However, there are results that
show that positive results correlate with melanoma thickness [60]. Initial results from 30-
month follow-up of the Sunbelt Melanoma Trial did not show any difference in disease-free
or overall survival in RT-PCR positive and negative patients [61]. The results were subse‐
quently included in meta-analysis where it has been suggested that RT-PCR may have val‐
uable prognostic use in the prediction of overall and disease free survival [62]. The clinical
relevance of the ability to detect micro-metastases by RT-PCR is still under investigation.
4.2. Elective regional lymph node dissection
Completion lymph node dissection (CLND) is recommended for patients with a positive
SLN biopsy. It is performed with the intention of halting metastatic spread of melanoma in
the early stages of the disease [15, 62, 64]. The five-year survival rate in patients with nega‐
tive complete lymph node dissection stands at 62.5%, compared with 20.3% in patients with
positive non-sentinel nodes [65]. However, the exact role of this and its reflection on overall
survival in the setting of positive sentinel nodes has yet to be fully elucidated.
Currently,  a  complete lymph node dissection is  carried out  for  all  patients  with a posi‐
tive sentinel lymph node, irrespective of the type of metastases (micro or macro-metasta‐
sis)  identified.  The value of  a complete lymph node dissection in this  group of patients
has not been extensively investigated and it must constantly be borne in mind that com‐
pletion  lymph  node  dissection  is  associated  with  significant  patient  morbidity  [66].  In‐
deed, in the MSLT-1, no improvement in OS was seen in the total group randomized to
receive  SLNB  followed  by  completion  lymph  node  dissection  (CLND)  if  the  SLN  was
positive compared to those randomized to WLE and observation, with nearly identical 5-
year melanoma specific-survival of 87.1% versus 86.6% (P = 0.58) [53]. Studies that looked
at this difference did not show any statistical significant between the two groups. In ad‐
dition, it is felt that micro-metastases will become evident if left untreated. Patients with
nodal metastases were shown to have a survival advantage with early intervention com‐
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pared with those who had a delayed lymphadenectomy only when they presented with
clinically evident nodal metastasis [15, 53, 67].
However,  a significant survival benefit  has been noted in patients with a positive senti‐
nel  lymph  node  biopsy,  who  undergo  a  complete  lymph  node  dissection,  when  com‐
pared with patients  undergoing complete  lymph node dissection after  nodal  metastases
become apparent  [68].  In  a  study conducted  by  Morton  et  al,  a  5-year  survival  rate  of
72%  was  seen  in  patients  with  positive  sentinel  lymph  nodes,  followed  by  immediate
lymph  node  dissection,  whereas  patients  undergoing  a  delayed  lymph  node  dissection
had a  5-year  survival  rate  of  only  52% [53].  Further  positive  non-sentinel  lymph nodes
are found in a relatively small  proportion of  patients:  previously quoted figures ranged
from 17%-24% [15, 69-71]. Interestingly a recent study has shown rates of further positive
findings to be as low as 14.8% [15, 53].
Researchers have sought to identify factors which may increase a patient’s likelihood of
non-sentinel node metastases. Increasing Breslow depth has been associated with increased
risk of non-sentinel node metastases, while a depth of less than 1mm has no association with
any further positive nodes on completion lymph node dissection [15,65]. Studies have failed
to show an association between specific tumour and patient characteristics with an in‐
creased rate of non-sentinel nodal metastasis [15, 71], However, a number of histopathologi‐
cal features have been shown to be associated with positive complete lymph node
dissections. These include: nodular melanoma, ulceration, melanoma regression, and nae‐
vus association [15, 65]. Using a size/ulceration score, Reeves et al. showed ulceration to be
an independent predictor of non-sentinel node deposits [72].
Recent  studies  have  examined  the  association  between  the  size  of  the  sentinel  lymph
node deposits and the rate of positive complete lymph node dissection. Kunte et al.  did
not report any patients with micro-metastatic deposits on sentinel lymph node biopsy to
have  positive  findings  on  complete  lymph  node  dissection  [15,  65,  73].  Another  study
showed a 3-year survival rate in patients with 1mm sentinel lymph node metastasis to be
100%, while 3-year survival in patients with deposits greater than 1mm was 80% [15, 74].
Ollila et al., however, found a significantly higher rate of recurrence in patients with sub-
micrometastatic  disease  (ie.  sentinel  lymph  node  deposits  less  than  0.1mm),  compared
with node-negative patients [15, 75].
A significant number of these questions will be address by the publication of the results of
The Multicenter Selective Lymphadenectomy Trial-II (MSTL-II) which are currently awaited
[76, 77]. This trial aims to address the importance of SLN metastases, the relevance of molec‐
ular assessment of the SLN and to evaluate the therapeutic benefit of CLNB after SLNB.
Within the trial, all patients with primary melanoma ≥1.2 mm or ≤1.2 mm with Clark level
IV / V or ulceration undergo a SLNB. This will be analyzed by both H&E and IHC techni‐
ques. Patients with a negative SLNB by H&E and IHC will undergo RT-PCR. All SLN-posi‐
tive patients identified by H&E/IHC or RT-PCR are randomized to one of two groups:
observation of lymph node basin with clinical examination and repeated follow-up ultra‐
sound scanning or to immediate CLND. Patients with negative SLN as determined by RT-
PCR are assigned to routine follow-up. The primary endpoint of this study is to determine if
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CLND will improve melanoma specific survival in patients with a positive SLNB. Secondary
endpoints include assessing the predictive value of immune responses to melanoma- associ‐
ated antigens, to analyze blood samples from patients for molecular markers of melanoma,
both before and after surgery and to assess the quality of life of patients undergoing either
CLND or observation after SLNB. Finally the study analyses the predictive value of certain
DNA markers of the primary tumor in relation to disease outcome [76, 77].
In conclusion, in the setting of a negative sentinel lymph node biopsy, a completion lymph
node dissection is clearly not indicated. The presence of positive nodes warrants considera‐
tion of complete lymph node dissection of the involved lymph node basin. Results of the
MSLT-II trial are awaited and will give answers to the option of nodal observation.
5. Management of distant metastatic disease
The management of patients with metastatic melanoma remains challenging. Despite im‐
proved therapeutic options the prognosis remains poor. A complete surgical resection of
metastatic disease in distant sites offers the best chance to improve survival. Patients with
in-transit metastasis may be offered further surgical resection of the lesions. Favourable
prognostic factors in patients with metastatic disease include a longer disease free survival,
single site disease, complete resection and non-visceral metastases [78]. Patients that under‐
go resection of their non-visceral metastasis have been shown to have a medium survival of
between 17 - 50 months, and a 5 - year survival of 9 - 35%. Patients with pulmonary metasta‐
sis, who have a complete resection, have a median survival of 8 - 20 months and a 5 year
survival of 10 -25%. Brain and gastrointestinal tract metastasis confers a median survival of
only 7-10 months [78]. Surgical resection in cases of advanced melanoma has been shown to
give good palliation, if all the disease is completely removed. More recently, new systemic
biological therapies have been developed, and when combined with surgery may be shown
to aid in improved survival. These combinations, however, are still under review [79].
Chemotherapeutic agents have little role to play in the management of metastatic melano‐
ma. Regimens that have previously been utilised include dacarbazine, temozolomide, high
dose interleukin-2, paclitaxel and cisplatin or carboplatin. These show a response rate of less
than 20% [33]. There is little evidence of its value in metastatic melanoma, however with
combination treatments their role is yet to be fully examined.
In 2011, the FDA approved two newer therapies for metastasis melanoma. These include
the  highly  selective  BRAF inhibitor,  vemurafenib,  and ipilimumab,  a  fully  human IgG1
monoclonal antibody. Around 40% to 60% of melanomas are shown to harbor a mutation
in the gene encoding for the serine /  threonine kinase protein kinase B-raf  (BRAF) with
90% of the mutations resulting in a substitution of valine for glutamate at amino acid 600
(V600E) [80]. Mutated BRAF leads to constitutive activation of the mitogen-activated pro‐
tein kinase pathway (MAPK) that in turn increases cellular proliferation and drives onco‐
genic  activity.  Sorafenib,  the  initial  BRAF  inhibitor  failed  to  demonstrate  significant
response rates in melanoma and its use has been largely discontinued. Vemurafenib is a
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newer highly selective inhibitor with promising results. The main limitation of this novel
agent is its limited response with an approximately 40% to 50% response rate in patients
with a V600-mutated BRAF gene. Unfortunately, the median duration of response is only
5 to 6 months [33]. GSK2118436 is a newer highly selective inhibitor of BRAF that is still
in pre-clinical trials [80].
Melanoma is an immunogenic tumor. Ipilimumab is a monoclonal antibody directed to the
cytotoxic T lymphocyte antigen-4 (CTLA-4). Results of two randomized phase III trial of pa‐
tients with unresectable metastatic disease that progressed during systemic therapy showed
an overall improvement in survival in patients randomized to the ipilimumab arm
[33,81,82]). In another phase III study looking at the role of ipilumumab and dacarbazine in
patients with previously untreated metastatic melanoma, ipilumumab and dacarbazine was
shown to have improved patient survival in comparison to the group receiving dacarbazine
alone [83[. The limitation of ipilimumab is its association with autoimmune toxicity. In addi‐
tion, clinical responses may take months to become apparent, and the overall response rate
is less than 20% [33]. Research is ongoing in this area. The EORTC18071 trial is ongoing and
compares adjuvant treatment with ipilimumab with observation in patients with high risk
lymph node positive disease [84].
The role of biochemotherapy has also been studied. This involves using a combination of
chemotherapy and biologic agents [33]. The results, however, show no additional surviv‐
al benefit with this treatment. Finally, palliative radiotherapy may have a role in the set‐
ting of metastatic melanoma and has been shown to have good palliation of symptomatic
disease [85-87].
6. Staging
An updated Cancer Staging Manual was recently published by the AJCC [7]. Modifications
of the melanoma staging guidelines, which have been used since 2002, were based on a mul‐
tivariate analysis on 38,918 patients [8]. In the revised guidelines melanoma patients have
been categorised into 3 groups; those with localised disease with no evidence of metastases
(stage I - II), patients with regional disease (stage III), and those with distant metastatic dis‐
ease (stage IV). Primary tumour thickness remains the factor most associated with progno‐
sis. Tumour thickness is defined in even integers (1.0, 2.0 and 4.0mm) with increasing
thickness corresponding with worsening survival. Within each tumour thickness category,
the presence of ulceration further upgrades the classification (Table 3).
Mitotic rate is an indicator of tumour proliferation and is measured as the number of mito‐
ses per mm2. Several studies have shown the mitotic rate to be an independent prognostic
factor in patients with melanoma [88-91]. The AJCC guidelines now recommend the “hot
spot” technique for calculating the mitotic rate, where the pathologist begins the mitotic
count with the most active tumour focus. This is calculated as mitosis/mm2 [8]. Multiple
thresholds of mitotic rate were examined statistically, and the most significant correlation
with survival was identified at a threshold of at least 1/mm2, where a mitotic rate greater
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than or equal to 1/mm2 was found to be independently associated with a poorer disease-spe‐
cific survival in patients with T1 disease. For non-ulcerated, thin melanomas the 10-year sur‐
vival was 95% if there were fewer than 1 mitosis per mm2, compared with 88% 10-year
survival if at least one mitosis per mm2 was present. In addition, the level of invasion, as
defined by Wallace Clark, was found to have no statistical significance in staging with the
mitotic rate replacing it as an upstaging criterion from stages 1a to 1b [92].
T Classification Thickness Ulceration status/mitosis
Tx
Primary tumour cannot be assessed (for
example, curettaged or severely regressed
melanoma)
T0 No evidence of primary tumor
Tis Melanoma in situ
T1 Melanoma is 1.0mm or less in thickness a: without ulceration and mitosis <1/mm2b: with ulceration or mitoses ≥1/mm2
T2 Melanoma 1.01-2.0mm a: without ulcerationb: with ulceration
T3 Melanoma 2.01- 4.0mm a: without ulcerationb: with ulceration
T4 Melanoma more than 4.0mm a: without ulcerationb: with ulceration
Table 3. T Classification as recommended by the AJCC [7]
Stage III patients have documented lymph node metastasis (microscopic of macroscopic)
(Table 4). S-100 is the most sensitive marker for melanocytic lesions while others such as
HMB-45, MART-1/Melan-A, tyrosinase, and MITF are very specific but less sensitive [93]. In
terms of documenting micro-metastasis, the AJCC accepts immunohistochemical staining of
at least one melanoma specific marker to make the diagnosis. Around 5% to 40% of patients
will be upstaged to stage III based on the presence of micro-metastatic disease. These pa‐
tients have a better prognosis than those presenting with macro-metastatic disease as shown
in several studies [8, 95]. The new AJCC guidelines reviewed the results of 3307 patients and
make a clear distinction between each group. Staging of this group includes defining the
number of nodes involved, the presence of microscopic versus macroscopic disease, as well
as intra-lymphatic (in-transit or satellite) metastasis, the presence or absence of primary tu‐
mour ulceration, and the thickness of the primary melanoma. These factors were found to be
predictive of survival on multivariate analysis. In the absence of nodal metastases, patients
with intra-lymphatic metastases (N2c) have 5-year and 10-year survival rates of 69% and
52%, respectively while those with combined intra-lymphatic metastases and nodal metasta‐
ses (N3) have survival rates of 46% and 33%, respectively [8].
Melanoma - From Early Detection to Treatment426
N Classification Nodes involved Nodal metastatic mass
Nx Regional nodes cannot be assessed (for example,previously removed for another reason)
N0 No regional metastasis noted
N1 1 node a: micro-metastasisb: macro-metastasis
N2 2-3 nodes
a: micro-metastasis
b: macro-metastasis
c: in transit mets(s)/ satellite(s) without
metastatic nodes
N3
4 or more metastatic nodes, or matted nodes, or
in transit met(s)/ satellite(s) with metastatic
node(s)
Table 4. N Classification as recommended by the AJCC [7]
Finally, the database for stage IV patients was expanded to include 7972 patients and the
new guidelines now incorporate the serum lactate dehydrogenase as a prognostic marker
included in staging (Table 5). An elevated serum LDH was found to be an independent and
a highly significant predictor of survival outcome. In a study that looked at the correlation
between survival in advanced melanoma from two large trials (Oblimersen GM301 and
EORTC 189510), the authors reported an elevated LDH in melanoma patients compared to
the normal population. A relationship was found between LD and survival [95]. Patients
with elevated serum LDH at diagnosis of melanoma are staged as M1c according to the
AJCC guidelines.
M Classification Site Serum LDH
M0 No detectable evidence of distant metastases
M1a Metastases to skin, subcutaneous, or distant lymphnodes Normal
M1b Metastases to lung Normal
M1c
Metastases to all other visceral sites or distant
metastases to any site combined with an elevated
serum LDH
Normal- visceral met(s)
Elevated- Distant met(s)
Table 5. M Classification as recommended by the AJCC [7]
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7. Follow-up
All patients with invasive melanoma should be followed up post-operatively, except for pa‐
tients with melanoma in-situ. The aim of follow-up is to detect evidence of recurrent disease
or a new primary melanoma early [97,98]. The primary site and adjacent skin should be ex‐
amined for recurrence of new suspicious lesions, as well as the draining lymph node basins
[23]. It is estimated that the lifetime risk of developing a second melanoma is around 4 - 6%.
Furthermore, around 60 - 80% of recurrences are found at local and/or regional nodal sites.
Around two thirds of these will occur within the first three years, 16% after the first five
years. Recurrence after more than ten years is also recognised [23].
There is little evidence for the optimum protocol for follow-up. It appears reasonable that all
patients with invasive melanoma should be followed up 6-monthly for 2 years. Thereafter,
those with melanomas less than 1.0 mm in depth may be discharged from routine follow-up;
other patients should be followed up for a further 3 years at 6-monthly intervals. Patients
with stage III or IV disease require lifelong follow up [23].
8. Conclusion
The incidence of melanoma continues to rise steadily in the Western World. Despite increased
awareness of the disease this does not appear to have a significant impact on its overall poor
prognosis. Surgery remains the mainstay of treatment as there is little in the way of adjuvant
systemic treatment. Adequate surgical margins with or without local reconstruction can im‐
prove local recurrence rates. The utilisation of the sentinel lymph node biopsy has allowed for
accurate staging of the disease. The finding of positive sentinel lymph nodes requires patients to
undergo further regional lymph node dissection to reduce the risk of loco-regional disease. The
impact of this on overall survival has not yet been clearly elucidated. Increased understanding
of the melanoma pathogenesis and molecular biology may lead to the development of novel
promising therapeutic agents and individualised treatment plans for these patients..
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